Bayer's Monsanto unit is in a Missouri courtroom this week seeking final approval of a $7.25 billion settlement designed to put years of Roundup litigation to rest. Judge Timothy Boyer is weighing the deal, which would resolve tens of thousands of current and future U.S. lawsuits alleging that glyphosate — the active ingredient in Roundup — causes non-Hodgkin lymphoma. The settlement was announced in February, following a prior ~$10 billion deal in 2020 that left Bayer exposed to future claims.

The legal landscape shifted significantly in June when the U.S. Supreme Court ruled 7-2 that federal pesticide law preempts state-level "failure-to-warn" claims against Bayer — a development that has weakened thousands of pending lawsuits. Proponents of the settlement argue it guarantees compensation in an increasingly uncertain litigation environment, while opponents contend the payouts are too low and the framework unfairly limits claimants' options.

By the Numbers:

• $7.25 billion — total proposed settlement value
• ~65,000 — current Roundup claims in U.S. state and federal courts
• $10,000–$165,000 — payout range per claimant, based on cancer severity, age at diagnosis, and exposure type
• 7-2 — Supreme Court vote in June that curtailed state-level failure-to-warn suits
• $1.25 million — the Missouri jury award overturned by the Supreme Court

Why it matters: The outcome of this hearing could mark the end of one of the most prolonged product liability battles in U.S. history, with significant implications for how federal pesticide law shields manufacturers from state tort claims — and what recourse cancer patients have when federal regulators and scientific bodies disagree on risk.